Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF

Steven Nathan, MD, discusses the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release,” which aimed to assess the effectiveness of oral nalbuphine extended release in providing relief from chronic cough in patients with IPF; the study used a clinical trial design to evaluate cough severity, with results showing that nalbuphine significantly reduced cough frequency and intensity, offering a potential new treatment option for managing this common and debilitating symptom of IPF.

EP: 1.CHEST 2024: Updates in IPF and PAH Care

EP: 2.Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry

EP: 3.Implications of IPF Survival Data for Clinical Practice and Early Intervention

Now Viewing

EP: 4.Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF

EP: 5.Insights on Managing Cough Symptoms in Patients With IPF

EP: 6.Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH

EP: 7.Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF

1. Briefly describe the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release.”
   1. What was the objective of this study?
   2. How was this study designed/what methodology was used?
   3. What results were presented?

Related Videos